Michael Benkowitz Sells 10,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) COO Michael Benkowitz sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $353.64, for a total value of $3,536,400.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $911,330.28. This trade represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, January 27th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $370.71, for a total value of $3,707,100.00.
• On Tuesday, January 21st, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00.
• On Monday, January 13th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $364.62, for a total value of $3,646,200.00.
• On Monday, December 30th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $356.68, for a total transaction of $3,566,800.00.
• On Monday, December 23rd, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $361.95, for a total value of $3,619,500.00.
• On Monday, November 25th, Michael Benkowitz sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $372.75, for a total value of $3,727,500.00.
• On Monday, November 11th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The stock was sold at an average price of $407.32, for a total transaction of $6,109,800.00.
• On Thursday, November 7th, Michael Benkowitz sold 15,000 shares of United Therapeutics stock. The shares were sold at an average price of $401.44, for a total transaction of $6,021,600.00.

United Therapeutics Stock Up 0.2 %

Shares of NASDAQ UTHR opened at $354.18 on Thursday. The company’s fifty day moving average is $363.80 and its 200-day moving average is $357.66. The stock has a market cap of $15.81 billion, a price-to-earnings ratio of 15.55, a P/E/G ratio of 0.92 and a beta of 0.57. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the company. Oppenheimer raised their price objective on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. TD Cowen boosted their price objective on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a research report on Monday, October 21st. UBS Group lifted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. HC Wainwright boosted their target price on United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Finally, The Goldman Sachs Group boosted their target price on shares of United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $382.08.

Hedge Funds Weigh In On United Therapeutics

Several institutional investors have recently modified their holdings of UTHR. World Investment Advisors LLC bought a new position in United Therapeutics in the third quarter valued at $139,206,000. FMR LLC boosted its holdings in shares of United Therapeutics by 41.1% during the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after buying an additional 314,004 shares during the period. AustralianSuper Pty Ltd increased its stake in shares of United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company’s stock worth $66,962,000 after purchasing an additional 161,751 shares during the period. Assetmark Inc. boosted its position in shares of United Therapeutics by 56.9% in the third quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock valued at $150,492,000 after acquiring an additional 152,249 shares during the period. Finally, Franklin Resources Inc. raised its position in shares of United Therapeutics by 97.7% in the third quarter. Franklin Resources Inc. now owns 250,719 shares of the biotechnology company’s stock valued at $89,532,000 after buying an additional 123,929 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.